In vitro binding analysis of legacy-linear and new generation-cyclic perfluoro-alkyl substances on sex hormone binding globulin and albumin, suggests low impact on serum hormone kinetics of testosterone.

Displacement Endocrine disruptor Isothermal titration calorimetry Serum half-life Tryptophan fluorescence quencing

Journal

Toxicology
ISSN: 1879-3185
Titre abrégé: Toxicology
Pays: Ireland
ID NLM: 0361055

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 07 07 2023
revised: 27 10 2023
accepted: 30 10 2023
pubmed: 7 11 2023
medline: 7 11 2023
entrez: 6 11 2023
Statut: ppublish

Résumé

In humans, serum testosterone (T) is largely bound to the sex hormone binding globulin (SHBG) and human serum albumin (hSA), resulting in a 2-3 % of unbound or "free" active quote (FT). Endocrine-disrupting chemicals, including perfluoro-alkyl substances (PFAS), are recognized to interfere with the hormonal axes, but the possible impact on the FT quote has not been addressed so far. Here we investigated the possible competition of two acknowledged PFAS molecules on T binding to SHBG and hSA. In particular, perfluoro-octanoic acid (PFOA) and acetic acid, 2,2-difluoro-2-((2,2,4,5-tetrafluoro-5(trifluoromethoxy)-1,3-dioxolan-4-yl)oxy)-ammonium salt (1:1) (C6O4) were used as, respectively, legacy-linear and new-generation-cyclic PFASs. Human recombinant SHBG 30-234 domain (SHBG

Identifiants

pubmed: 37931871
pii: S0300-483X(23)00251-2
doi: 10.1016/j.tox.2023.153664
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

153664

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Angela Pavan (A)

Department of Biology, University of Padova, Padova, Italy.

Laura Cendron (L)

Department of Biology, University of Padova, Padova, Italy.

Andrea Di Nisio (A)

Deparment of Medicine, Unit of Andrology and Reproductive Medicine, University of Padova, Padova, Italy.

Federica Pedrucci (F)

Deparment of Medicine, Unit of Andrology and Reproductive Medicine, University of Padova, Padova, Italy.

Iva Sabovic (I)

Deparment of Medicine, Unit of Andrology and Reproductive Medicine, University of Padova, Padova, Italy.

Alessandro Scarso (A)

Department of Molecular Sciences and Nanosystems, Università Ca' Foscari Venezia, Venezia, Italy.

Alberto Ferlin (A)

Deparment of Medicine, Unit of Andrology and Reproductive Medicine, University of Padova, Padova, Italy.

Alessandro Angelini (A)

Department of Molecular Sciences and Nanosystems, Università Ca' Foscari Venezia, Venezia, Italy; European Centre for Living Technology (ECLT), Ca' Bottacin, Venice, Italy.

Carlo Foresta (C)

Deparment of Medicine, Unit of Andrology and Reproductive Medicine, University of Padova, Padova, Italy. Electronic address: carlo.foresta@unipd.it.

Luca De Toni (L)

Deparment of Medicine, Unit of Andrology and Reproductive Medicine, University of Padova, Padova, Italy.

Classifications MeSH